0 of 7 questions completed
You have already completed the quiz before. Hence you can not start it again.
Quiz is loading...
You must sign in or sign up to start the quiz.
You have to finish following quiz, to start this quiz:
Currently, how confident are you in your ability to:
1 = not confident, 2 = somewhat confident, 3 = confident, 4 = very confident, 5 = extremely confident, N/A = not applicable to me
Apply recent and emerging clinical trial data when developing personalized treatment plans for patients with an acute major bleed associated with direct oral anticoagulants
Utilize the interprofessional team in the management and treatment of patients with an acute major bleed
Indicate how often you CURRENTLY use each of the following clinical practice strategies for your patients with an acute major bleed.
*1 = Never, 2 = Not often, 3 = Sometimes, 4 = Often, 5 = Always, N/A = Not applicable to me
Utilize current strategies to treat direct oral anticoagulant associated bleeds in emergent situations
Evaluate and incorporate recent clinical trial data for the reversal of anticoagulation in Factor Xa
Integrate recent evidence-based science to individualized treatment strategies to improve outcomes in patients who require emergent reversal of their direct oral anticoagulant therapy
1. Which of the following is NOT a common characteristic for a patient with major bleeding who is taking a DOAC?
2. According to the 2017 ACC Decision Pathway on the Management of Bleeding in Patients on Oral Anticoagulants, which of the following represents the first step in how to manage a bleed?
3. In the study by Dr. Stuart Connolly, Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors, there were a total of 67 patients. These 67 patients were prescribed to three different therapeutic treatments. Which of the following is NOT one the three prescribe treatments?
4. The ANNEXA-4 Study had both key eligibility inclusion and exclusion criteria. Which of the following is considered an inclusion criteria?
5. In the ANNEXA-4 Study Safety Assessment, thrombotic events occurred within 3 days of andexanet in 6 patients (2.6%) and within 30 days in how many patients?